Posted by Michael Wonder on 29 Jul 2017
‘It’s very frustrating’: ovarian cancer patient waiting on potential approval of new treatment
27 July 2017 - Seventy-five women are diagnosed with ovarian cancer in Saskatchewan each year, and fifty-five lose their lives.
But does that outcome need be so severe? Ovarian Cancer Canada thinks not and it is hopeful a new drug can reduce that number.
Lynparza is designed to be a therapy treatment for women with BRCA-mutated ovarian cancer. BRCA is a gene deviation that makes women more prone to breast and ovarian cancer.
The drug has received approval from Health Canada, however it did not receive a recommendation from the pan-Canadian Oncology Drug Review (pCODR). The panel cited insufficient evidence, and asked for more data.
